CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-28	US$5.523	+0.10%	3,721
26-08-27	US$5.517	+1.42%	7,174
26-08-26	US$5.440	-6.21%	6,956
26-08-25	US$5.800	-2.36%	8,563
26-08-24	US$5.940	+1.89%	18,785

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.523USD

Average target price

10.00USD

Spread / Average Target

+81.06%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:30:00 2026-08-28 EDT			5-day change	1st Jan Change
5.523 ^USD	+0.10%		-5.27%	+5.20%

08-12	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-17	CNS Pharmaceuticals, Inc. - Special Call

Market Cap	8.07M 6.96M 6.52M 5.95M 11.21M 771M 11.25M 77.37M 30.19M 389M 30.3M 29.64M 1.29B	P/E 2026 *	-3.35x	P/E 2027 *	-3.33x
Enterprise Value	8.07M 6.96M 6.52M 5.95M 11.21M 771M 11.25M 77.37M 30.19M 389M 30.3M 29.64M 1.29B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	99.05%	Yield 2026 *	-	Yield 2027 *	-

08-12	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-17	CNS Pharmaceuticals, Inc. - Special Call
05-19	CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders	MT
05-18	CNS Pharmaceuticals, Inc. announced that it has received $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners and other investors	CI
05-14	CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Top Midday Gainers	MT
05-04	Top Premarket Gainers	MT
05-04	CNS Pharmaceuticals, Inc. Announces Board Changes, Effective May 4, 2026	CI
05-03	CNS Pharmaceuticals, Inc. announced that it expects to receive $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners and other investors	CI
03-31	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	CNS Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-02	CNS Pharmaceuticals, Inc. Announces Separation of Sandra Silberman as Chief Medical Officer, Effective as of March 2, 2026	CI
03-02	CNS Pharmaceuticals, Inc. Announces Chief Medical Officer Changes, Effective March 2, 2026	CI

24-06-26	Top Midday Decliners	MT
22-08-17	Maxim Downgrades CNS Pharmaceuticals to Hold From Buy	MT
21-02-02	CNS Pharmaceuticals : Brookline Capital Initiates Coverage on CNS Pharmaceuticals at Buy Rating, Sets Price Target at $10	MT
20-12-28	CNS Pharmaceuticals : Ladenburg Thalmann Downgrades CNS Pharmaceuticals to Neutral From Buy	MT

CNS Pharmaceuticals, Inc. Stock

Stocks

CNSP

US18978H5081

Biotechnology & Medical Research

Valuation : CNS Pharmaceuticals, Inc.

Chart: CNS Pharmaceuticals, Inc.

Latest news : CNS Pharmaceuticals, Inc.

Last Transcript : CNS Pharmaceuticals, Inc.

Analysts' recommendations : CNS Pharmaceuticals, Inc.

Press Releases : CNS Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : CNS Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

08-27	CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference	AQ
08-12	CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation	AQ
06-08	CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment	AQ
05-14	CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress	AQ
05-04	CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing	AQ

1 day	+0.10%
1 week	-5.27%
Current month	-5.06%
1 month	+10.46%
3 months	+1.52%
6 months	+77.59%
Current year	+5.20%

1 week	5.44	6.19
1 month	4.81	6.19
Current year	1.9	10.54
1 year	1.9	10.59
3 years	1.9	82,500.08
5 years	1.9	1,530,015.3
10 years	1.9	5,120,961.21

Manager	Title	Age	Since
Rami Levin CEO	Chief Executive Officer	57	2025-12-31
Steve O'Loughlin DFI	Director of Finance/CFO	41	2026-03-01
E. Kelley CTO	Chief Tech/Sci/R&D Officer	63	2026-03-01

Director	Title	Age	Since
Jeffry Keyes BRD	Director/Board Member	53	2018-06-24
Faith Charles CHM	Chairman	64	2022-12-29
Bettina Cockroft BRD	Director/Board Member	59	2023-05-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/14/26	Rami Levin	Fiscal year	Chief Executive Officer	-9,500	0.6500%
5/18/26	Faith Charles	Buy	Chairman	7,100	0.8750%
3/2/26	Steve O'Loughlin	Free	Chief Financial Officer	9,500	1.5315%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CNS PHARMACEUTICALS, INC.	+0.10%	-5.27%	-10.92%	-99.99%	8.07M
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+93.70%	69.54B
ARGENX SE	-1.34%	-0.75%	+48.21%	+91.86%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	-0.69%	+52.56%	+10.23%	26.51B
INSMED INCORPORATED	-2.35%	-5.75%	-12.90%	+448.54%	25.89B
BIONTECH SE	-8.37%	-12.43%	+2.08%	-16.71%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+436.50%	20.22B
GENMAB A/S	-0.51%	+0.23%	+35.77%	-18.70%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-4.37%	+13.28%	+535.19%	15.69B
EXELIXIS, INC.	-1.47%	+0.68%	+45.51%	+143.08%	13.49B
Average	-1.81%	-2.26%	+50.90%	+162.37%	28.19B
Weighted average by Cap.	-1.93%	-1.50%	+53.73%	+151.50%

	2026 *	2027 *
Net sales	-	-
Net income	-13.02M -11.22M -10.52M -9.61M -18.1M -1.24B -18.15M -125M -48.71M -628M -48.9M -47.84M -2.08B	-21.68M -18.69M -17.52M -15.99M -30.13M -2.07B -30.22M -208M -81.1M -1.05B -81.41M -79.64M -3.47B
Net Debt	-	-